Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Increases By 94.4%

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the recipient of a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 272,900 shares, a growth of 94.4% from the June 15th total of 140,400 shares. Currently, 1.4% of the company’s stock are sold short. Based on an average daily volume of 117,000 shares, the short-interest ratio is presently 2.3 days.

Aileron Therapeutics Price Performance

NASDAQ:ALRN opened at $3.18 on Friday. The company’s fifty day moving average price is $3.31 and its 200-day moving average price is $4.29. Aileron Therapeutics has a 1-year low of $1.01 and a 1-year high of $7.42. The firm has a market capitalization of $68.72 million, a P/E ratio of -1.00 and a beta of 2.23.

Aileron Therapeutics (NASDAQ:ALRN) last posted its quarterly earnings data on Monday, May 20th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.72). Equities analysts anticipate that Aileron Therapeutics will post -1.36 EPS for the current fiscal year.

Insider Transactions at Aileron Therapeutics

In other news, major shareholder Of Texas/Texas Am I. University sold 20,315 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $4.21, for a total value of $85,526.15. Following the completion of the sale, the insider now owns 1,779,306 shares of the company’s stock, valued at approximately $7,490,878.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, major shareholder Of Texas/Texas Am I. University sold 20,315 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $4.21, for a total transaction of $85,526.15. Following the completion of the sale, the insider now owns 1,779,306 shares of the company’s stock, valued at $7,490,878.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Of Texas/Texas Am I. University sold 9,342 shares of the stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $3.25, for a total transaction of $30,361.50. Following the sale, the insider now directly owns 1,753,156 shares of the company’s stock, valued at approximately $5,697,757. The disclosure for this sale can be found here. In the last quarter, insiders sold 64,618 shares of company stock valued at $248,685. Company insiders own 5.57% of the company’s stock.

Hedge Funds Weigh In On Aileron Therapeutics

A hedge fund recently raised its stake in Aileron Therapeutics stock. Texas Capital Bank Wealth Management Services Inc lifted its holdings in Aileron Therapeutics, Inc. (NASDAQ:ALRN) by 65.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,171 shares of the company’s stock after buying an additional 10,398 shares during the period. Texas Capital Bank Wealth Management Services Inc owned approximately 0.16% of Aileron Therapeutics worth $174,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 90.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ALRN shares. Brookline Capital Management raised shares of Aileron Therapeutics to a “strong-buy” rating in a research report on Thursday, May 30th. LADENBURG THALM/SH SH upped their price target on shares of Aileron Therapeutics from $9.00 to $19.00 and gave the company a “buy” rating in a research note on Thursday, April 18th.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).